Alto Neuroscience ANRO Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -38.9%— | -41.8%— | —— | —— | —— | |
| Return on assets | -33.2%— | -34.9%— | -36.8%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 20.5×-2.0× | 15.7×-1.2× | 15.4×+2.3× | 18.4×— | 22.5×— | |
| Quick ratio | 20.5×-2.0× | 15.7×-1.2× | 15.4×+2.3× | 18.4×— | 22.5×— | |
| Cash ratio | 20.1×-2.1× | 15.6×-1.2× | 15.3×+2.3× | 18.2×— | 22.2×— | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×0.0× | 0.2×— | 0.2×— | 0.2×— | |
| Debt-to-assets | 0.1×-0.1× | 0.1×0.0× | 0.2×+0.1× | 0.2×— | 0.1×— | |
| Interest coverage | -32.2×+10.7× | -26.9×+23.0× | -29.8×+15.6× | -36.5×— | -43×— | |
| Per Share | ||||||
| Book value per share | $7.40+43.9% | $5.24-14.9% | $4.12-32.8% | $4.56-31.8% | $5.14-53.1% | |
| Valuation | ||||||
| Market capitalization | $887.88M+1,358% | $552.98M+385% | $108.85M— | $67.68M— | $58.48M— | |
| Enterprise value | $644.49M-958% | $397.73M+1,120% | -$4.07M— | -$55.1M— | -$77.55M— | |
| Price / book | 3.6×+3.2× | 3.7×+2.9× | 1×— | 0.5×— | 0.4×— | |
| Free cash flow yield | -7.1%+83.0pp | -9.4%+34.0pp | -49.4%— | -83.7%— | -93.8%— | |
| Earnings yield | -8.4%+95.4pp | -11.4%+42.4pp | -57.2%— | -95.8%— | -108%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Alto Neuroscience's ratios come from?
- Every ratio is computed from Alto Neuroscience's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.